3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Lymphoma
7
Breast Neoplasms
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myeloid, Acute
5
Multiple Myeloma
4
Lymphoma, T-Cell, Cutaneous
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Leukemia
3
Glioblastoma
3
Brain Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neoplasms
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Interventions
Rituximab
4
Etoposide
3
cobomarsen
2
Vincristine
2
Prednisone
2
Ifosfamide
2
Doxorubicin
2
Cyclophosphamide
2
Carboplatin
2
ponatinib
1
ibritumomab tiuxetan
1
dacetuzumab
1
Vorinostat
1
Melphalan
1
Imatinib Mesylate
1
Cytarabine
1
Carmustine
1
Brentuximab Vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Immunoproliferative Disorders
×
Vorinostat
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts